Michael Davidson to Diabetes Mellitus
This is a "connection" page, showing publications Michael Davidson has written about Diabetes Mellitus.
Connection Strength
2.165
-
The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
Score: 0.304
-
AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
Score: 0.278
-
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
Score: 0.242
-
Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
Score: 0.215
-
Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. J Clin Lipidol. 2010 Jan-Feb; 4(1):72-3; discussion 74.
Score: 0.193
-
Inhaled human insulin: an inspiration for patients with diabetes mellitus? Cleve Clin J Med. 2006 Jun; 73(6):569-78.
Score: 0.150
-
Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 Nov 23; 63(10):1902-7.
Score: 0.135
-
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study. Clin Lung Cancer. 2024 01; 25(1):e35-e42.
Score: 0.125
-
Combination lipid-lowering therapy in diabetes. Curr Diab Rep. 2003 Jun; 3(3):263-8.
Score: 0.122
-
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
Score: 0.048
-
Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
Score: 0.047
-
Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008 Jan; 21(1):92-7.
Score: 0.042
-
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008; 28(10):615-23.
Score: 0.042
-
Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
Score: 0.037
-
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
Score: 0.036
-
C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005 Aug 30; 112(9):1289-95.
Score: 0.036
-
Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus. Am J Cardiol. 2005 Jan 01; 95(1):123-6.
Score: 0.034
-
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
Score: 0.031
-
Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
Score: 0.028
-
LIMITATIONS IN THE USE OF ORAL HYPOGLYCEMIC AGENTS IN JUVENILE PATIENTS WITH DIABETES. J Pediatr. 1965 May; 66:844-56.
Score: 0.009
-
Treating dyslipidemia in high-risk patients: case reviews and discussion. Postgrad Med. 2004 Sep; 116(3 Suppl):21-8.
Score: 0.008
-
Short-term effects of coping skills training as adjunct to intensive therapy in adolescents. Diabetes Care. 1998 Jun; 21(6):902-8.
Score: 0.005